Cargando…

Anti-Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptor Encephalitis: A Review

Anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) encephalitis, a rare subtype of autoimmune encephalitis, was first reported by Lai et al. The AMPAR antibodies target against extracellular epitopes of the GluA1 or GluA2 subunits of the receptor. AMPARs are expressed thr...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Tian-Yi, Cai, Meng-Ting, Zheng, Yang, Lai, Qi-Lun, Shen, Chun-Hong, Qiao, Song, Zhang, Yin-Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175895/
https://www.ncbi.nlm.nih.gov/pubmed/34093540
http://dx.doi.org/10.3389/fimmu.2021.652820
_version_ 1783703143235715072
author Zhang, Tian-Yi
Cai, Meng-Ting
Zheng, Yang
Lai, Qi-Lun
Shen, Chun-Hong
Qiao, Song
Zhang, Yin-Xi
author_facet Zhang, Tian-Yi
Cai, Meng-Ting
Zheng, Yang
Lai, Qi-Lun
Shen, Chun-Hong
Qiao, Song
Zhang, Yin-Xi
author_sort Zhang, Tian-Yi
collection PubMed
description Anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) encephalitis, a rare subtype of autoimmune encephalitis, was first reported by Lai et al. The AMPAR antibodies target against extracellular epitopes of the GluA1 or GluA2 subunits of the receptor. AMPARs are expressed throughout the central nervous system, especially in the hippocampus and other limbic regions. Anti-AMPAR encephalitis was more common in middle-aged women and most patients had an acute or subacute onset. Limbic encephalitis, a classic syndrome of anti-AMPAR encephalitis, was clinically characterized by a subacute disturbance of short-term memory loss, confusion, abnormal behavior and seizure. Magnetic resonance imaging often showed T2/fluid-attenuated inversion-recovery hyperintensities in the bilateral medial temporal lobe. For suspected patients, paired serum and cerebrospinal fluid (CSF) testing with cell-based assay were recommended. CSF specimen was preferred given its higher sensitivity. Most patients with anti-AMPAR encephalitis were complicated with tumors, such as thymoma, small cell lung cancer, breast cancer, and ovarian cancer. First-line treatments included high-dose steroids, intravenous immunoglobulin and plasma exchange. Second-line treatments, including rituximab and cyclophosphamide, can be initiated in patients who were non-reactive to first-line treatment. Most patients with anti-AMPAR encephalitis showed a partial neurologic response to immunotherapy.
format Online
Article
Text
id pubmed-8175895
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81758952021-06-05 Anti-Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptor Encephalitis: A Review Zhang, Tian-Yi Cai, Meng-Ting Zheng, Yang Lai, Qi-Lun Shen, Chun-Hong Qiao, Song Zhang, Yin-Xi Front Immunol Immunology Anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) encephalitis, a rare subtype of autoimmune encephalitis, was first reported by Lai et al. The AMPAR antibodies target against extracellular epitopes of the GluA1 or GluA2 subunits of the receptor. AMPARs are expressed throughout the central nervous system, especially in the hippocampus and other limbic regions. Anti-AMPAR encephalitis was more common in middle-aged women and most patients had an acute or subacute onset. Limbic encephalitis, a classic syndrome of anti-AMPAR encephalitis, was clinically characterized by a subacute disturbance of short-term memory loss, confusion, abnormal behavior and seizure. Magnetic resonance imaging often showed T2/fluid-attenuated inversion-recovery hyperintensities in the bilateral medial temporal lobe. For suspected patients, paired serum and cerebrospinal fluid (CSF) testing with cell-based assay were recommended. CSF specimen was preferred given its higher sensitivity. Most patients with anti-AMPAR encephalitis were complicated with tumors, such as thymoma, small cell lung cancer, breast cancer, and ovarian cancer. First-line treatments included high-dose steroids, intravenous immunoglobulin and plasma exchange. Second-line treatments, including rituximab and cyclophosphamide, can be initiated in patients who were non-reactive to first-line treatment. Most patients with anti-AMPAR encephalitis showed a partial neurologic response to immunotherapy. Frontiers Media S.A. 2021-05-21 /pmc/articles/PMC8175895/ /pubmed/34093540 http://dx.doi.org/10.3389/fimmu.2021.652820 Text en Copyright © 2021 Zhang, Cai, Zheng, Lai, Shen, Qiao and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zhang, Tian-Yi
Cai, Meng-Ting
Zheng, Yang
Lai, Qi-Lun
Shen, Chun-Hong
Qiao, Song
Zhang, Yin-Xi
Anti-Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptor Encephalitis: A Review
title Anti-Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptor Encephalitis: A Review
title_full Anti-Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptor Encephalitis: A Review
title_fullStr Anti-Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptor Encephalitis: A Review
title_full_unstemmed Anti-Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptor Encephalitis: A Review
title_short Anti-Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptor Encephalitis: A Review
title_sort anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor encephalitis: a review
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175895/
https://www.ncbi.nlm.nih.gov/pubmed/34093540
http://dx.doi.org/10.3389/fimmu.2021.652820
work_keys_str_mv AT zhangtianyi antialphaamino3hydroxy5methyl4isoxazolepropionicacidreceptorencephalitisareview
AT caimengting antialphaamino3hydroxy5methyl4isoxazolepropionicacidreceptorencephalitisareview
AT zhengyang antialphaamino3hydroxy5methyl4isoxazolepropionicacidreceptorencephalitisareview
AT laiqilun antialphaamino3hydroxy5methyl4isoxazolepropionicacidreceptorencephalitisareview
AT shenchunhong antialphaamino3hydroxy5methyl4isoxazolepropionicacidreceptorencephalitisareview
AT qiaosong antialphaamino3hydroxy5methyl4isoxazolepropionicacidreceptorencephalitisareview
AT zhangyinxi antialphaamino3hydroxy5methyl4isoxazolepropionicacidreceptorencephalitisareview